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Poster Session-II 12130% at 1 year after HCT and 26% at 2 years. Adult patients who had
steroid-refractory GVHD within 2 weeks of onset had a 1-year sur-
vival of 16% compared to 88% among steroid refractory pediatric
patients. During the 14 day periods immediately before or after
the onset of GI symptoms, these risk factors for overall mortality
were identified by multivariable analysis.
Risk factors for mortality in 117 patients with stage 3/4 gut
GVHD
Univariate MultivariateHR (95% CI) P-value HR (95% CI) P-valueStage at onset
3 (n544) 1.0 1.0
4 (n573) 2.09 (1.3–3.3) 0.001 1.87 (1.1–3.1) 0.01
Steroid refractory
No (n537) 1.0 1.0
Yes (n580) 2.4 (1.5–3.9) 0.0002 2.11 (1.2–3.6) 0.005
Age at transplant
#18 (n515) 1.0 1.0
$18 (n5102) 3.84 (1.7–8.8) 0.0001 3.64 (1.5–8.7) 0.0008
Bilirrubin
#3.0 (n558) 1.0 1.0
$3 (n559) 2.88 (1.9–4.4) \0.0001 2.52 (1.6–4.0) 0.0001
Albumin
.1.6 (n585) 1.0 1.0
#1.6 (n532) 2.74 (1.7–4.3) \0.0001 1.69 (1.0–2.8) 0.05
Regimen related toxicity
No (n557) 1.0 1.0
Yes (n560) 0.81 (0.5–1.2) 0.33
Upper endoscopy1 (clinical)
0-2 (n565) 1.0 1.0
31 (n511) 2.91 (1.5–5.7) 0.005 2.45 (1.2–5.2) 0.03
Upper endoscopy1 (biopsy)
0-2 (n570) 1.0 1.0
31 (n56) 2.41 (1.0–2.7) 0.07
Lower endoscopy2 (clinical)
0-2 (n535) 1.0 1.0
31 (n511) 1.23 (0.6–2.5) 0.58
Lower endoscopy2 (biopsy)
0-2 (n526) 1.0 1.0
31 (n520) 1.43 (0.7–2.7) 0.28
CT scan30,1 (n528) 1.0 1.0
2 (n512) 0.48 (0.2–1.2) 0.091available in 76 patients (term for missing included in multivariate model)
2available in 46 patients
3available in 40 patients. All covariates are based on the ‘worst’ assess-
ment prior to and including the interval of onset
In a subgroup of patients who underwent endoscopy (N 5 73),
a finding of ulcerated mucosa was predictive of mortality (HR
2.52, p 5 0.02). Within 2 weeks of GI symptom onset, mortality
in patients with GVHD can be predicted by age, jaundice, hypoalbu-
minemia, response to prednisone, and presence of ulcerated mucosa
at endoscopy. More effective early treatment in GI GVHD patients
at risk for mortality is likely to be more useful than salvage therapy
for steroid-refractory patients.337
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Redirecting specificity of human T cells to tumor antigens using
chimeric antigen receptors (CARs) is a promising approach for adop-tive cell therapy. Non-viral gene transfer of a CD19-specific CAR
into human peripheral blood mononuclear cell (PBMC)-derived T
cells using the Sleeping Beauty system is undergoing evaluation in
the autologous setting. We now are developing allogeneic CAR1 T
cells for infusion after hematopoietic stem-cell transplantation
(HSCT) to improve the graft-versus-leukemia (GvL) effect. How-
ever, CAR1 T cells possess endogenous T-cell receptors (TCR) re-
taining broad TCR Vb subfamily distribution, and may therefore
mediate alloresponses to histocompatibility antigens. Alloanergiza-
tion of donor-derivedT cells (induction of alloantigen-specific hypo-
responsiveness by allostimulation with blockade of CD28-mediated
costimulation) is a simple and clinically-proven approach to selec-
tively abrogate alloresponses. We therefore assessed whether alloa-
nergization could reduce alloresponses in CAR1 T cells without
loss of CD19-specific redirected killing. Alloproliferative responses
were detected in CAR1 T cells generated from healthy donors
when co-cultured with HLA-mismatched irradiated stimulator
PBMC.To reduce potential forGvHD,CAR1Tcells were alloaner-
gized by co-culture with stimulator PBMC and clinical-grade hu-
manized monoclonal anti-B7.1 and -B7.2 antibodies, resulting in
a median 75% reduction in subsequent stimulator-specific allores-
ponses without loss of proliferation tomitogenic CD3. Alloanergiza-
tion was further improved (median 93% reduction in alloresponses)
with use of CD19-depleted stimulator PBMC to remove non-allo-
specificB cell-mediated stimulation ofCAR1Tcells. Importantly al-
loanergized CAR1 T cells retained CD19-specific CAR expression
and CD19-specific killing. In aggregate, as allogeneic CAR1 T cells
exhibit alloproliferative responses in vitro they have potential to cause
GvHD. To overcome this potential problem, we have demonstrated
that deleterious alloresponses can be abrogated by the clinically-ap-
plicable technique of alloanergization without loss of proliferation
to mitogenic stimulus, expression of CAR, or specific killing of
CD191 targets. Thus, two techniques, CAR insertion and alloanerg-
ization, that have both achieved regulatory approval can be employed
together to produce non-alloreactive donor T cells for clinical use to
augment GvL after allogeneic HSCT for B-cell malignancies.338
IN VITRO POLARIZED TH17 CELLS INDUCE SEVERE ACUTE GRAFT-VER-
SUS-HOST DISEASE
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Contribution of different T cell subsets in the development of
graft-versus-host disease (GVHD) is an active area of research. T
helper type-1 (Th1) cells were believed to be the most important
CD4 T cell subset to induce GVHD through inflammatory cyto-
kines including IFNg and TNFa. However, the concept was seri-
ously challenged by recent findings that T cells deficient for IFNg,
Stat4 or T-bet caused exacerbated GVHD. These results indicate
that Th1 subset is not required for the induction of GVHD and
other Th subsets are sufficient. Th17 is a newly identified T cell lin-
eage that secretes IL-17A among other pro-inflammatory cytokines.
Th17 cells play a critical role in autoimmune diseases, including
causing a systemic autoimmune disorder resembling GVHD. How-
ever, the role of Th17 cells in the pathogenesis of classical GVHD
remains unclear. In the current study, by transferring in vitro gener-
ated Th17 cells together with donor bone marrow into lethally irra-
diated allogeneic recipients, we demonstrated that allogeneic Th17
cells were highly pathogenic to induce GVHD, more so than naı¨ve
or Th1 controls. The same Th17 cells, however, caused no pathol-
ogy in the syngeneic recipients, indicating antigen-activation was re-
quired for these cells to induce GVHD. High potency of Th17 cells
in the induction of GVHDwas correlated with their superior ability
to expand and to infiltrate in GVHD target organs. After transfer
into recipients, Th17 cells produced significant levels of IFNg and
TNFa besides IL-17A. Furthermore, IFNg KO Th17 cells had re-
duced ability to cause GVHD compared to wild type (WT) Th17
cells, indicating that IFNg also contributes to the pathogenicity of
Th17 cells. Our findings show that both Th1 and Th17 cells
participate in the pathogenesis of acute GVHD.
